References
Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine: a review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989; 38: 389–416
Frezza M, Terpin M. The use of S-adenosyl-L-methionine in the treatment of cholestatic disease: a meta-analysis of clinical trials. Drug Invest 1992; 4 Suppl. 4: 101–8
Pinals RS. Pharmacologic treatment of osteoarthritis. Clin Ther 1992; 14: 336–46
Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-Adenosylmethionine) in neurological disorders. Drugs 1994; 48: 137–52
Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: metaanalysis of clinical studies. Acta Neurol Scand 1994; Suppl. 154: 7–14
British National Formulary No. 27. London: The Pharmaceutical Press, 1994; 157
De Vanna M, Rigamondi R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992; 52: 478–85
Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992; 44: 257–62
Carrieri PB, Indaco A, Gentile S. et al. S-adenosylmethionine treatment of depression in patients with Parkinson’s disease. Curr Ther Res 1990; 48: 154–60
Iruela LM, Minguez L, Merino J, et al. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993; 150: 522
Rights and permissions
About this article
Cite this article
Ademetionine has clinical potential in depression. Drugs Ther. Perspect 5, 8–9 (1995). https://doi.org/10.2165/00042310-199505020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199505020-00003